Company news

Share this article:
Teva Pharmaceuticals has announced the completion of its acquisition of Barr Pharmaceuticals, for $7.46 billion, plus the assumption of roughly $1.5 billion in debt. Barr's generic business in the US will extend Teva's product portfolio, while adding a substantial women's healthcare business, among other things, said Shlomo Yanai, Teva president and CEO, in a statement.

A US district court in California has dismissed a lawsuit against Amgen that claimed the company had promoted two anemia drugs – Epogen and Aranesp – off-label. The court said government regulators, and not private companies or individuals, had the right to bring such an action. The lawsuit was filed as a class action suit, involving claims made by seven health benefit plan providers.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.